Fig. 3 | Scientific Reports

Fig. 3

From: Spinal chordoma and chondrosarcoma treatment experiences - a 20-year retrospective study from databases of two medical centers

Fig. 3

(A) Overall survival (OS) between R2-margined patients with or without radiation therapy (RT). The mean OS for R2 patients, with and without RT, was 105.5 ± 26.2 and 76.0 ± 9.2 months, respectively (p value = 0.734). The predicted 5-year survival rates for each group were 51.6 ± 17.8% and 78.0 ± 11.4%, while the anticipated 10-year survival rates were 51.6 ± 17.8% and 9.8 ± 9.2%. (B) Progression-Free survival (PFS) between R2-margined patients with or without radiation therapy. Among R2 patients, the mean PFS was 27.1 ± 6.4 months for those who underwent RT and 22.9 ± 7.8 months for those who did not (p value = 0.513).

Back to article page